EpiCypher Expands Exclusive Licensing Agreement to Advance CUT&Tag Technology
DURHAM, N.C., Sept. 4, 2024 /PRNewswire/ — EpiCypher®, a trailblazer in epigenetic research technologies, is pleased to announce an exclusive licensing agreement with Fred Hutch Cancer Center. This agreement grants EpiCypher access to pivotal intellectual property (IP) related to CUT&Tag technology, a revolutionary advancement in chromatin profiling developed by renowned scientist Dr. Steven Henikoff, a Fred Hutch molecular biologist and Howard Hughes Medical Institute Investigator.
